Update shared on04 Oct 2025
Fair value Decreased 1.49%Glaukos' analyst consensus price target has been revised slightly lower, from $122.46 to $120.64, as analysts cite near-term reimbursement bottlenecks. This is offset by improving sentiment surrounding the company's accelerating iDose trajectory and favorable long-term market positioning.
Analyst Commentary
Recent research notes reflect both optimism and caution regarding Glaukos, as analysts assess the company’s prospects amid shifting market dynamics and near-term industry challenges.
Bullish Takeaways- Bullish analysts remain confident in the long-term trajectory of the iDose product, viewing survey results as affirming its potential for sustained growth.
- Some see the recent share price selloff as overdone and highlight an opportunity for investors to accumulate shares at what they view as attractive valuations.
- There is mounting optimism that reimbursement bottlenecks are starting to ease, with more physician fees being established. This could accelerate revenue growth into 2026.
- Calmer inflation and favorable currency movements are noted as macroeconomic tailwinds supporting market conditions for Glaukos.
- Bears note ongoing concerns about reimbursement headwinds, which may continue to create volatility in near-term financial performance.
- The broader MedTech sector remains under pressure, with fears of Medicaid cuts and hospital closures casting a shadow on sentiment and potentially impacting execution.
- Persistent market caution is reflected in mixed sentiment. Analysts are watching for clarity during earnings season as opinions on valuation remain highly divided.
- Some price targets have been revised down as analysts factor in the speed at which reimbursement issues will resolve and the timeline for acceleration of iDose growth.
What's in the News
- Glaukos celebrated the groundbreaking of a new 200,000 square-foot research, development, and manufacturing facility in Huntsville, Alabama. The facility is expected to create more than 150 full-time jobs and be completed by 2030 (Key Developments).
- The new facility represents a planned capital investment of over $80 million, with options for future expansion on an additional 15 acres (Key Developments).
- Glaukos raised its 2025 net sales guidance to a range of $480 million to $486 million, citing favorable foreign currency exchange rates (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has decreased slightly from $122.46 to $120.64. This reflects a modest reduction in perceived fair value.
- Discount Rate has edged down from 7.50 percent to 7.42 percent, which indicates a marginally more favorable risk outlook.
- Revenue Growth projection is largely unchanged, moving marginally lower from 25.56 percent to 25.54 percent.
- Net Profit Margin estimate has fallen from 8.44 percent to 7.84 percent. This suggests tempered profitability expectations.
- Future P/E ratio has risen from 134.64x to 142.54x, signaling increased valuation relative to anticipated earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.